Stock Watch: Biopharma Caught In US Government Anti-Bundling Drive
Two Big Issues, One Common Factor
Executive Summary
Medicare price renegotiation and the FTC’s scrutiny of biopharma acquisitions have suppressed sector stock prices. But the sector may not be the actual target.
You may also be interested in...
First Round Of Drugs Up For Medicare Negotiation Gets Soft Landing
Big pharma valuations mostly held steady as CMS released its list of the first 10 drugs subject to Medicare negotiations under the Inflation Reduction Act, which held few surprises and included products nearing the end of their patent lives by the time negotiated pricing takes effect.
Big Rebates Already A Big Factor For Drugs On Medicare Negotiation List
Long-awaited list has a couple of surprises that are expected to face biosimilar competition either before negotiated prices are implemented in 2026 or during that year.
Pfizer Shakes Up R&D Leadership, Streamlining Oncology Ahead Of Seagen Merger
Chief development officer William Pao will depart the company in a sudden transition after being recruited from Roche. Pfizer insiders Chris Boshoff and Mikael Dolsten will fill the roles.